Fractional flow reserve-guided management in stable coronary disease and acute myocardial infarction: recent developments

Abstract

Coronary artery disease (CAD) is a leading global cause of morbidity and mortality, and improvements in the diagnosis and treatment of CAD can reduce the health and economic burden of this condition. Fractional flow reserve (FFR) is an evidence-based diagnostic test of the physiological significance of a coronary artery stenosis. Fractional flow reserve is a pressure-derived index of the maximal achievable myocardial blood flow in the presence of an epicardial coronary stenosis as a ratio to maximum achievable flow if that artery were normal. When compared with standard angiography-guided management, FFR disclosure is impactful on the decision for revascularization and clinical outcomes. In this article, we review recent developments with FFR in patients with stable CAD and recent myocardial infarction. Specifically, we review novel developments in our understanding of CAD pathophysiology, diagnostic applications, prognostic studies, clinical trials, and clinical guidelines.

<p>Metformin Activates the AMPK-mTOR Pathway by Modulating lncRNA <em>TUG1</em> to Induce Autophagy and Inhibit Atherosclerosis</p>

“…Atherosclerotic diseases such as CHD remain the leading cause of death worldwide; the lifetime risk of CHD is 67% in humans over 55 years of age. [27][28][29] Studies have shown that lncRNAs are vital regulatory factors in the progression of AS. [30][31][32] Thus, defining their functions might help to identify novel diagnostic and therapeutic targets for AS.…”

Clinical effect of atorvastatin-trimetazidine combined treatment of coronary heart disease

“…As a common Tatins lipid-lowering drug, atorvastatin reduces cholesterol content in blood plasma by inhibiting synthesis of HMG-CoA reductase and cholesterol inside the liver, thereby facilitating LDL ingestion and catabolism and lowering LDL level by increasing quantity of LDL receptors on hepatocyte surface [8,9]. As a kind of piperazine derivative, trimetazidine can accelerate transformation of myocardial fatty acid metabolism in blood into glucose metabolism, inhibit generation of oxygen radicals, increase myocardial output quantity, stabilize intracellular environment, and improve myocardial functions [10].…”

Acute Coronary Syndrome Mimicking Takotsubo Cardiomyopathy or Takotsubo Cardiomyopathy Mimicking Acute Coronary Syndrome?

“…Should we consider this presentation to be an acute coronary syndrome (ACS) related to the mid-LAD unstable plaque being the culprit lesion and implement percutaneous intervention (PCI), which in turn carries some risk, particularly in complex cases [1,2]? Or a TTC with a typical apical ballooning [3,4]-which pathogenic mechanism is believed to be linked to microvascular dysfunction [5] and catecholamine cardiotoxicity [6]-with a significant but innocent concomitant mid-LAD coronary artery disease and therefore treat medically?…”